Description du projet
L’IA et les capteurs intelligents pour améliorer la gestion de la bronchopneumopathie chronique obstructive
Le terme de bronchopneumopathie chronique obstructive (BPCO) désigne un groupe de maladies associées à des problèmes respiratoires qui touchent des millions de personnes dans le monde. La BPCO est très hétérogène, nécessitant des approches de traitement et de gestion personnalisées. Cependant, en raison des effets extrapulmonaires et des comorbidités, les patients ne répondent souvent pas aux traitements pharmacologiques et non-pharmacologiques. Pour remédier à ce problème, le projet TOLIFE financé par l’UE propose de développer une solution d’IA qui traite les données de la vie quotidienne des patients saisies par de discrets capteurs. La plateforme basée sur l’IA permettra de prédire les exacerbations de la BPCO et d’évaluer l’état de santé des patients. Un outil de gestion des patients permettra ensuite aux cliniciens de proposer un traitement précoce et personnalisé, améliorant ainsi la qualité de vie des personnes affectées.
Objectif
Chronic obstructive pulmonary disease (COPD) is a highly prevalent chronic condition. While COPD is a lung disease, it is mainly the exacerbations and extrapulmonary comorbidities which affect the quality of life, health care costs, and prognosis. The optimal COPD treatment needs to focus on both the characteristics and consequences of the lung disease itself and the diagnosis and treatment of comorbidities. While the severity of lung function impairment is routinely assessed, the exacerbations, the associated comorbidities and limitations in daily life are still significantly underestimated. A personalized approach to COPD management is needed to specifically address the disease, prevent exacerbations, and mitigate its comorbidities to obtain a positive impact on patient health and quality of life.
TOLIFE will clinically validate an artificial intelligence (AI) solution to process daily life patient data captured by unobtrusive sensors to enable optimised personalised treatment, assessment of health outcomes and improved quality of life in COPD patients. The TOLIFE approach to COPD management, targeted to predict and mitigate exacerbations and continuously assess the health outcomes, has the potential to reduce mortality, improve health related quality of life and reduce the healthcare costs.
TOLIFE will develop and clinically validate an AI-based platform for the early prediction of exacerbations and assessment of the health outcomes. Prediction of exacerbations and assessment of health outcomes will be exploited by clinicians through a patient management tool to perform early and personalized treatment. TOLIFE platform will inform through a disease information tool the patient and caregivers about the patient's health status, the specific treatment plan and lifestyle indications. Two clinical studies will be implemented, one to collect data for AI-tools development and the other to validate the effectiveness of TOLIFE to reduce the risk of exacerbations.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
56126 Pisa
Italie